SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

PMCB RSS Feed
Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Peacefulwendy, $Pistol Pete$, thenewmixer, fraum, concordia
Search This Board: 
Last Post: 10/21/2017 1:16:55 AM - Followers: 779 - Board type: Free - Posts Today: 2

Welcome to PharmaCyte BioTech
An OTCQB Company

PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its "cancer" killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one-third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver (where ifosfamide is normally activated) and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a "bio-artificial pancreas" for purposes of insulin production.






 


 





FDA Grants Orphan Drug Designation to Pharmacyte Biotech for Pancreatic Cancer Treatment



European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation to PharmaCyte’s subsidiary,
PharmaCyte Biotech Europe Limited, for PharmaCyte’s pancreatic cancer treatment

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000395.jsp&mid=WC0b01ac058001d12b

 Company Address
   
PharmaCyte Biotech, Inc.

23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92652
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com
http://pharmacyte.com/
 

Market Value:
$122,386,272 a/o Dec 19, 2016

Shares Outstanding:
848,904,665 a/o Aug 29, 2016

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

Float:
817,204,665 a/o Aug 29, 2016


For more updated information please visit: 


http://www.otcmarkets.com/stock/PMCB/profile


Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations


Stonegate Capital Inc.
8201 Preston Road
Suite 325
Dallas, TX 75225
United States

 

   All News Releases: 

http://www.pharmacytebiotech.com/news/

 


What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans.


http://austrianova.com/products/ 



Management Team:

Kenneth L. Waggoner, Chief Executive Officer and President
 

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director


Carlos A. Trujillo – Chief Financial Officer and Director


Walter H. Gunzburg – Chief Scientific Officer


Dr. Matthias Lohr as Chairman of Scientific Advisory Board


Thomas Liquard - Chairman of the Audit Committe

  Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development

Dr. Manuel Hidalgo, Scientific Advisory Board

 


 

 

 


***DISCLAIMER***
-  The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
-  We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
-  There are no guarantees when buying or selling any security.





 
 


                                   

 
 
SureTrader
Interactive Brokers Advertisement
PMCB
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PMCB News: Current Report Filing (8-k) 10/10/2017 08:31:01 AM
PMCB News: Notice of Effectiveness (effect) 09/29/2017 06:01:57 AM
PMCB News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/28/2017 04:18:18 PM
PMCB News: Securities Registration Statement (simplified Form) (s-3) 09/13/2017 09:26:54 AM
PMCB News: Quarterly Report (10-q) 09/13/2017 06:06:08 AM
PostSubject
#76603  Sticky Note $PMCB PharmaCyte Biotech Research Identifies Enzyme Acti $Pistol Pete$ 10/19/17 02:45:54 AM
#62231  Sticky Note in full/ #2/ 01-28-2017/ Keeping an Eye on mick 01/28/17 07:35:33 PM
#52881  Sticky Note Here is a very nice list of accomplishments... Peacefulwendy 09/28/16 11:17:44 AM
#76726   Four years ago or so, .50 to .60 mwebb1514 10/21/17 01:16:55 AM
#76725   If we learn anything from history it’s that frosr6 10/21/17 01:04:30 AM
#76724   Or waggs could reveal something that sends it efood125 10/20/17 11:56:30 PM
#76723   I'm waiting for nov 1 to see what tulla236a 10/20/17 09:34:17 PM
#76722   Why don’t we call for a shareholder meeting? 1234jklm 10/20/17 09:20:58 PM
#76721   Read the compensation committee charter on the website. tulla236a 10/20/17 08:56:03 PM
#76720   Does this company publish an annual report? 1234jklm 10/20/17 08:48:14 PM
#76719   I understand and don't blame you. And tulla236a 10/20/17 08:34:13 PM
#76718   Smart move. Feels good to be out doesn’t frosr6 10/20/17 08:25:51 PM
#76717   Good luck and enjoy the weekend ;-) Go $PMCB $Pistol Pete$ 10/20/17 07:54:32 PM
#76716   I've closed out my position until IND which fraum 10/20/17 06:36:40 PM
#76715   I agree with you RC...I too criticized waggs efood125 10/20/17 06:30:33 PM
#76714   Maybe Bionic Kenny will explain how they will concordia 10/20/17 04:26:27 PM
#76713   it is clear from today's pr PMCB will thenewmixer 10/20/17 04:02:33 PM
#76712   "The home stretch". "Been working for three Intotheblack 10/20/17 03:23:23 PM
#76710   all PMCB videos staged by smmg KK the insider thenewmixer 10/20/17 02:40:32 PM
#76709   TGen receives $2.5 million SU2C grant for new concordia 10/20/17 02:29:18 PM
#76708   I respect you have a right to your Brian903 10/20/17 02:21:20 PM
#76707   If Lohr is that great and respected why concordia 10/20/17 02:19:18 PM
#76706   27:10 go there in video Brian903 10/20/17 02:14:42 PM
#76705   Obviously the pre-clinicals were not as good as concordia 10/20/17 02:02:55 PM
#76704   Amazing..results..for..ascites and not even mentioned in the update 1234jklm 10/20/17 01:48:23 PM
#76702  Restored Agreed esusun 10/20/17 12:42:26 PM
#76701   What shorts are you speaking of? Less then concordia 10/20/17 12:32:33 PM
#76700   You can tell by the ask that this Intotheblack 10/20/17 12:03:43 PM
#76699   THE problem is that KW basically controls the mind1 10/20/17 11:40:11 AM
#76698   Agreed $Pistol Pete$ 10/20/17 11:08:24 AM
#76697   It's just going to make the squeeze produce Intotheblack 10/20/17 11:07:49 AM
#76696   The work have being done and get ready $Pistol Pete$ 10/20/17 11:02:10 AM
#76694   I’m not discussing your right to an opinion 1234jklm 10/20/17 10:52:37 AM
#76693   It's my opinion. I can base it on rcstock 10/20/17 10:47:12 AM
#76691   Of course but base it on facts please 1234jklm 10/20/17 10:44:37 AM
#76689   I can if I wish. rcstock 10/20/17 10:40:48 AM
#76688   KW is the ceo the buck stop there.....if thenewmixer 10/20/17 10:39:34 AM
#76687   Optimistic thinking not based on reality 1234jklm 10/20/17 10:39:06 AM
#76686   Don’t apologize for him 1234jklm 10/20/17 10:38:00 AM
#76685   I can recall the opposition...complaining for the news ferenc 10/20/17 10:36:26 AM
#76684   In defense of KW. rcstock 10/20/17 10:29:49 AM
#76683   yeah we all know.... Pancreatic Cancer Awareness Month thenewmixer 10/20/17 10:29:25 AM
#76682   11/1 is significant, the bears don't see it. Intotheblack 10/20/17 10:11:02 AM
#76681   Kenneth Waggoner. Asleep at the wheel. 1234jklm 10/20/17 09:57:38 AM
#76680   I like the technology but don't trust kw. JODI1 10/20/17 09:53:49 AM
#76679   again no live question so KW will pick thenewmixer 10/20/17 09:44:22 AM
#76678   Still thinking about the last shareholder call and markiff 10/20/17 09:43:43 AM
#76677   Kw is unmotivated imho 1234jklm 10/20/17 09:42:03 AM
#76676   Don't mean to be picky but I would Mens et Manus 10/20/17 09:31:04 AM
#76675   Kudos to KW !He is meeting his 1st rcstock 10/20/17 09:30:53 AM
#76674   Can't wait for the lawyer speak on 11/1/17. concordia 10/20/17 09:26:49 AM
#76673   In the time permitted for the call? 1234jklm 10/20/17 09:14:36 AM
#76672   $PMCB PharmaCyte Biotech to Hold Shareholder Call PMC $Pistol Pete$ 10/20/17 09:06:26 AM
PostSubject